According to a recent LinkedIn post from Neuromod Devices Ltd, the company’s Lenire tinnitus treatment device is now available in the Netherlands through HearConsult locations in Utrecht and Mijdrecht. The post highlights that this expands access in a market where more than 2 million adults are affected by tinnitus and where incidence reportedly rose 33% between 2012 and 2021.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post references an individual user experience from an Utrecht-based researcher who reports a reduction in tinnitus disturbance after using Lenire, alongside mention of supporting clinical research. For investors, the move suggests Neuromod is targeting a growing European tinnitus market, which could support incremental revenue growth and strengthen its competitive position in neuromodulation-based hearing and tinnitus care.
By partnering with HearConsult, the post implies Neuromod is using established audiology channels rather than direct-to-consumer distribution in the Netherlands. This approach may accelerate adoption, improve clinician buy-in, and provide a template for further geographic expansion across Europe if patient outcomes and demand remain supportive.